[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100651911":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":11,"centralContacts":28,"locations":34,"responsibleParty":52,"collaborators":11,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":11,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":11,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":76,"whyStopped":11,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Chengdu Zenitar Biomedical Technology Co., Ltd","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Part A","EXPERIMENTAL",null,[13],"Drug: 75mg Flonoltinib",{"label":15,"type":10,"description":11,"interventionNames":16},"Part B",[17],"Drug: 100mg Flonoltinib",[19,24],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","75mg Flonoltinib","Day 1 and Day 12 : 75mg Flonoltinib on an empty stomach in the morning",[9],{"type":20,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"100mg Flonoltinib","Day 1 and Day 19 : 100mg Flonoltinib on an empty stomach in the morning",[15],[29],{"name":30,"role":31,"phone":32,"phoneExt":11,"email":33},"Wang Fangmei","CONTACT","+8613808086495","fangmei.wang@zenitar.cn",[35],{"facility":36,"status":11,"city":37,"state":38,"zip":11,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"The Second Affiliated Hospital of Anhui Medical University","Hefei","Anhui","China","CN",{"type":42,"coordinates":43},"Point",[44,45],117.28083,31.86389,{"lat":45,"lon":44},[48],{"name":49,"role":31,"phone":50,"phoneExt":11,"email":51},"Zhang Jing","+86 551-63806061","aydefyllwyhbgs@163.com",{"type":53,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100651911","phase-1-clinical-study-on-drug-interactions-of-flonoltinib-maleate-tablets-100651911",false,"NCT07768111","Clinical Study on Drug Interactions of Flonoltinib Maleate Tablets","A Single-Center, Open, Fixed-Sequence Clinical Drug Interaction Study Evaluating the Effects of Itraconazole or Rifampicin on the Pharmacokinetic Profile of Flonoltinib Maleate Tablets in Healthy Participants","Inclusion Criteria:\n\n1. Chinese healthy adult , aged 18-45 years old\n2. During the screening period, participants male weight \\>=50.0 kg, female weight \\>=45.0 kg and having a body mass index (BMI) between 19.0 and 26.0 kg\u002Fm\\^2\n3. Fully understand the purpose and requirements of this trial, voluntarily participate in the clinical trial and sign a written informed consent form, and be able to complete the entire trial process according to the trial requirements.\n\nExclusion Criteria:\n\n1. Screening period electrocardiogram examination: Fridericia formula (QTcF=QT\u002F(RR \\^ 0.33)) corrected QT interval (QTcF)\\>450 milliseconds\n2. HBsAg,HBeAg, hepatitis C antibody, treponema pallidum antibody or HIV Ag\u002FAb combined test\n3. Individuals with a history of drug abuse or drug use, or positive urine drug abuse screening results\n4. Individuals who have consumed any food or beverage containing alcohol, grapefruit juice\u002Fgrapefruit juice, or methylxanthine (such as coffee, tea, cola, chocolate, functional drinks) within 48 hours prior to check-in\n5. Individuals with a history of needle or blood dizziness, difficulty in blood collection, or intolerance to venipuncture blood collection",true,"ALL","18 Years","45 Years",{"count":66,"type":67},40,"ESTIMATED","INTERVENTIONAL",[70],"PHASE1","This study is a single center, open label, fixed sequence drug interaction study to evaluate the effects of CYP3A4 inhibitor itraconazole and CYP3A4 inducer rifampicin on the pharmacokinetic characteristics of a single oral dose of flonotinib maleate tablets.\n\nThis trial includes screening period, baseline period, medication observation period, and follow-up period, totaling approximately 3 months.",[73],"Drug Interaction Research",[75],"FM","NOT_YET_RECRUITING","2026-08-17",{"date":79,"type":80},"2026-08-19","ACTUAL",{"date":82,"type":67},"2026-10-30",{"date":84,"type":67},"2027-01-31",{"name":5,"class":6},1]